유전성 검사 시장 : 질병 유형, 기술, 용도, 최종 사용자별 - 세계 예측(2025-2030년)

The Hereditary Testing Market was valued at USD 5.15 billion in 2023, expected to reach USD 5.57 billion in 2024, and is projected to grow at a CAGR of 8.17%, to USD 8.93 billion by 2030.

Hereditary testing, also known as genetic testing, involves analyzing DNA to identify changes in genes, chromosomes, or proteins, helping detect genetic disorders. The scope of hereditary testing encompasses diagnostic, predictive, and carrier testing, as well as prenatal and newborn screening. Its necessity is driven by the increasing need for early disease detection, personalized medicine, and growing public awareness about genetic disorders. It is applied in various areas, including oncology, cardiology, and neurology, catering to healthcare professionals, patients, and researchers. Market growth is primarily influenced by technological advancements like next-generation sequencing, increased government funding, and a rising prevalence of genetic diseases. Opportunities lie in expanding personalized medicine within emerging markets, and the integration of AI for data analysis and interpretation can enhance testing accuracy and speed. Recommendations to seize these opportunities include investing in R&D to improve test accuracy and affordability, and fostering collaborations with healthcare providers for wider reach.

However, the market faces challenges such as regulatory hurdles, ethical concerns surrounding genetic privacy, and potential insurance coverage limitations. Overcoming these limitations requires robust data privacy measures and public education initiatives to alleviate ethical concerns. Innovative areas for growth include non-invasive prenatal testing, expansion into pharmacogenomics, and the development of direct-to-consumer testing kits. The market is highly dynamic, characterized by increased competition and rapid technological advancements, necessitating continuous innovation and adaptation. Companies might focus on increasing affordability and awareness through strategic partnerships and marketing campaigns. Overall, leveraging the intersection of technology and healthcare will be crucial for capitalizing on the booming hereditary testing market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hereditary Testing Market

The Hereditary Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Exploration for changes or variants, in DNA to find root cause of potential disease
  • Increased screening by pregnant women
  • Rising R&D activities on advance Genome sequencing
• Market Restraints
  • Limited reimbursement policies
• Market Opportunities
  • Collaborative product development
  • Attractive investment and amalgamation activity within value chain
• Market Challenges
  • Uncertain outcomes of the hereditary testing

Porter's Five Forces: A Strategic Tool for Navigating the Hereditary Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hereditary Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hereditary Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hereditary Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hereditary Testing Market

A detailed market share analysis in the Hereditary Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hereditary Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hereditary Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hereditary Testing Market

A strategic analysis of the Hereditary Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hereditary Testing Market, highlighting leading vendors and their innovative profiles. These include BGI Genomics Co., Ltd., Biocartis NV, CENTOGENE N.V., CooperSurgical, Inc., CSL Behring, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd., Invitae Corporation, Konica Minolta, Inc., Medgenome, Myriad Genetics, Inc., Natera Inc., Quest Diagnostics Incorporated, Siemens Healthineers AG, and SOPHiA Genetics.

Market Segmentation & Coverage

This research report categorizes the Hereditary Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Disease Type, market is studied across Hereditary Cancer Testing, Hereditary Non-Cancer Testing, Newborn Genetic Screening, Non-Invasive Prenatal Testing & Carrier Screening Tests, and Preimplantation Genetic Diagnosis & Screening. The Hereditary Cancer Testing is further studied across Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma, Stomach or Gastric Cancer, and Uterine Cancer. The Hereditary Non-Cancer Testing is further studied across Genetic Tests. The Genetic Tests is further studied across Cardiac Diseases and Rare Diseases.
• Based on Technology, market is studied across Biochemical, Cytogenetic, and Molecular Testing.
• Based on Application, market is studied across Cancer Diagnosis, Cardiovascular Disease Diagnosis, and Genetic Disease Diagnosis.
• Based on End-User, market is studied across Clinics and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Exploration for changes or variants, in DNA to find root cause of potential disease
    • 5.1.1.2. Increased screening by pregnant women
    • 5.1.1.3. Rising R&D activities on advance Genome sequencing
  • 5.1.2. Restraints
    • 5.1.2.1. Limited reimbursement policies
  • 5.1.3. Opportunities
    • 5.1.3.1. Collaborative product development
    • 5.1.3.2. Attractive investment and amalgamation activity within value chain
  • 5.1.4. Challenges
    • 5.1.4.1. Uncertain outcomes of the hereditary testing
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Hereditary Testing Market, by Disease Type

• 6.1. Introduction
• 6.2. Hereditary Cancer Testing
  • 6.2.1. Breast Cancer
  • 6.2.2. Cervical Cancer
  • 6.2.3. Colorectal Cancer
  • 6.2.4. Lung Cancer
  • 6.2.5. Melanoma
  • 6.2.6. Ovarian Cancer
  • 6.2.7. Pancreatic Cancer
  • 6.2.8. Prostate Cancer
  • 6.2.9. Sarcoma
  • 6.2.10. Stomach or Gastric Cancer
  • 6.2.11. Uterine Cancer
• 6.3. Hereditary Non-Cancer Testing
  • 6.3.1. Genetic Tests
    • 6.3.1.1. Cardiac Diseases
    • 6.3.1.2. Rare Diseases
• 6.4. Newborn Genetic Screening
• 6.5. Non-Invasive Prenatal Testing & Carrier Screening Tests
• 6.6. Preimplantation Genetic Diagnosis & Screening

7. Hereditary Testing Market, by Technology

• 7.1. Introduction
• 7.2. Biochemical
• 7.3. Cytogenetic
• 7.4. Molecular Testing

8. Hereditary Testing Market, by Application

• 8.1. Introduction
• 8.2. Cancer Diagnosis
• 8.3. Cardiovascular Disease Diagnosis
• 8.4. Genetic Disease Diagnosis

9. Hereditary Testing Market, by End-User

• 9.1. Introduction
• 9.2. Clinics
• 9.3. Hospitals

10. Americas Hereditary Testing Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Hereditary Testing Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Hereditary Testing Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. BGI Genomics Co., Ltd.
• 2. Biocartis NV
• 3. CENTOGENE N.V.
• 4. CooperSurgical, Inc.
• 5. CSL Behring
• 6. Eurofins Scientific SE
• 7. F. Hoffmann-La Roche Ltd.
• 8. Invitae Corporation
• 9. Konica Minolta, Inc.
• 10. Medgenome
• 11. Myriad Genetics, Inc.
• 12. Natera Inc.
• 13. Quest Diagnostics Incorporated
• 14. Siemens Healthineers AG
• 15. SOPHiA Genetics